Arcutis Biotherapeutics Inc., ARQT, FDA Calendar, PDUFA Date

Company Name	Arcutis Biotherapeutics Inc. ARQT
Drug Name	ZORYVE cream 0.3% (sNDA)
Event Name	FDA decision on ZORYVE cream 0.3% to expand indication for the topical treatment of plaque psoriasis to include children 2 to 5 years old
Event Date	06/29/2026
Outcome Date
Outcome	Pending
Drug Status	If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2
Rival Drugs
Market Potential
Other Approvals	ZORYVE cream 0.3% is currently approved for plaque psoriasis in adults and children down to age 6.
News

Return to FDA Calendar

RELATED NEWS (Arcutis Biotherapeutics Inc.)

Slide Shows